NCT01797900View on ClinicalTrials.gov

The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

PHASE2CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG

Cisplatin

induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64

DRUG

Paclitaxel

induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64

RADIATION

IMRT

69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume

Trial Locations (1)

100021

Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors

lead

Chinese Academy of Medical Sciences

OTHER

NCT01797900 - The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | Biotech Hunter | Biotech Hunter